<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Us ing Non–Contrast-Enhanced Computed Tomography" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/evaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/evaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2014-10-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Us ing Non–Contrast-Enhanced Computed Tomography" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2014-10-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Us ing Non–Contrast-Enhanced Computed Tomography","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/evaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast/"},"url":"https://clinicaltree.github.io/posts/evaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast/"}</script><title>Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Us ing Non–Contrast-Enhanced Computed Tomography | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Us ing Non–Contrast-Enhanced Computed Tomography</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Evaluation of Clinical Outcomes of Antiangiogenic-Targeted Therapy in Patients with Pulmonary Metastatic Renal Cell Carcinoma Us ing Non–Contrast-Enhanced Computed Tomography</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1414774800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Oct 31, 2014 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Guang-yu Wu MM</a> </em>, <em> <a href="">Shi-teng Suo MS</a> </em>, <em> <a href="">Wen Kong PhD</a> </em>, <em> <a href="">Di Jin PhD</a> </em>, <em> <a href="">Jin Zhang PhD</a> </em>, <em> <a href="">Jian-rong Xu PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1971 words"> <em>10 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The objective of this study was to assess whether changes to radiographic parameters before and after treatment with antiangiogenic drugs would improve performance in predicting tumor response with non–contrast-enhanced computed tomography (NCECT) compared to Response Evaluation Criteria in Solid Tumors (RECIST).</p><h2 id="material-and-methods"><span class="mr-2">Material and Methods</span><a href="#material-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The exploration sample group and the validation sample group consisted of 58 and 25 patients, respectively, who had pulmonary metastatic renal cell carcinoma and were receiving antiangiogenic drugs. All patients underwent NCECT scans at baseline and at first evaluation (after two cycles of treatment) with the same scan protocol. Tumor diameter, attenuation value, entropy, and uniformity of the exploration sample group were examined by receiver operating characteristic (ROC) analysis and stepwise discriminant analysis. The threshold value derived from ROC analysis and discriminant function of the exploration sample group were also used for the validation sample group and were compared to RECIST using Kaplan–Meier survival curves.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>According to the model obtained from the exploration group, Kaplan–Meier curves for patients without disease progression were significantly different for the discriminant analysis of the validation sample group ( <em>P</em> = .04) and better than individually using RECIST ( <em>P</em> = .08), percentage change for attenuation value ( <em>P</em> = .49), entropy ( <em>P</em> = .47, .89, .72, .73, and .58), and uniformity ( <em>P</em> = .53, .72, .51, .39, and .16; without filtration, at scale values of 1.0, 1.5, 2.0, and 2.5, respectively).</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Combined with changes to imaging parameters, including size, attenuation value, and uniformity between pre- and post-treatment, discrimination analysis can help predict biologic response to antiangiogenic drugs and provide a more accurate response assessment than RECIST criteria.</p><p>Renal cell carcinoma (RCC) is one of the most common cancers within the group of urogenital neoplasms . Approximately 30% of all other patients will develop metastases at a later stage of their disease. RCC is a tumor with high vascularization, and antiangiogenic drugs, including sorafenib, sunitinib, and axitinib, have demonstrated significant efficacy against metastatic RCC (mRCC) in clinical trials . Accurate evaluation is important when assessing response to therapy. Response Evaluation Criteria in Solid Tumours (RECIST), which is based on evaluation of tumor size, is the most wildly used classified method . However, recent studies have shown the inadequacy of RECIST for assessing therapeutic response in patients with mRCC who have received antiangiogenic-targeted therapy . Therefore, biomarkers other than size are needed for a better assessment of therapeutic response.</p><p>The application of imaging parameters including computed tomography (CT) texture for monitoring antiangiogenic efficacy has been reported in a recent study and been shown to be capable of depicting and monitoring tumor angiogenesis in patients, for which intravenous iodinated contrast is appropriate. However, renal impairment may preclude the use of intravenous iodinated contrast material in patients with renal disease . To the best of our knowledge, the use of imaging parameters including attenuation value, entropy, and uniformity of tumor for monitoring antiangiogenic efficacy in mRCC patients using non–contrast-enhanced CT (NCECT) has not been thoroughly explored. The objective of this study was to assess whether these imaging parameters will improve assessment of tumor response with NCECT instead of RECIST.</p><h2 id="material-and-methods-1"><span class="mr-2">Material and methods</span><a href="#material-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="ct-imaging"><span class="mr-2">CT Imaging</span><a href="#ct-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-analysis"><span class="mr-2">Image Analysis</span><a href="#image-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>entropy=∑ni=1(−pi)[log(pi)]anduniformity=∑ni=1[log(pi)]2 entropy</p><p>=</p><p>∑</p><p>i</p><p>=</p><p>1</p><p>n</p><p>(</p><p>−</p><p>p</p><p>i</p><p>)</p><p>[</p><p>log</p><p>(</p><p>p</p><p>i</p><p>)</p><p>]</p><p>and</p><p>uniformity</p><p>=</p><p>∑</p><p>i</p><p>=</p><p>1</p><p>n</p><p>[</p><p>log</p><p>(</p><p>p</p><p>i</p><p>)</p><p>]</p><p>2</p><p>where <em>i</em> is the pixel value in the ROI ( <em>i</em> = 1 to n, where <em>n</em> is the highest pixel value) and <em>p__i</em> is the probability of the occurrence of that pixel value. Higher entropy and lower uniformity represent increased heterogeneity . The scale was selected by tuning the filter parameters between 1.0 and 2.5, where 1.0 indicates fine texture (features 4 pixels in width), 1.5 and 2.0 indicate medium textures (features 6 and 10 pixels in width, respectively), and 2.5 indicates coarse texture (features 12 pixels in width).</p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EvaluationofClinicalOutcomesofAntiangiogenicTargetedTherapyinPatientswithPulmonaryMetastaticRenalCellCarcinomaUsingNonContrastEnhancedComputedTomography/0_1s20S1076633214002359.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EvaluationofClinicalOutcomesofAntiangiogenicTargetedTherapyinPatientswithPulmonaryMetastaticRenalCellCarcinomaUsingNonContrastEnhancedComputedTomography/0_1s20S1076633214002359.jpg" alt="Figure 1, (a) Computed tomography image of a left lower lobe lung metastasis. Images selectively display (b) fine, (c) medium, and (d) coarse texture obtained using values for image filtration of 1.0, 1.5, and 2.5, respectively." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-evaluation"><span class="mr-2">Statistical Evaluation</span><a href="#statistical-evaluation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Patient Demographics and Clinical Data</p><p>Characteristic Exploration Sample Validation Sample Number of patients 58 25 Gender Male 32 11 Female 26 14 Age Mean (range) 62 (42–78) 60 (44–71) Antiangiogenic-targeted therapy (number of patients) Sunitinib 41 12 Sorafenib 17 13</p><p>Table 2</p><p>Parameter Value and Percentage Change for Parameter of Patients at Baseline and After Two Treatment Cycles</p><p>Parameter Exploration Sample Validation Sample PFS &lt;1 year PFS ≧1 year PFS &lt;1 year PFS ≧ 1 year Size Bsl/AT (mm) 61.63 ± 5.73/69.58 ± 7.26 57.63 ± 9.87/58.22 ± 7.45 54.63 ± 2.74/59.83 ± 3.91 56.63 ± 5.75/55.45 ± 3.27 Change (%) 21.63 ± 38.11 1.31 ± 32.63 13.18 ± 33.67 −1.17 ± 22.63 AV Bsl/AT (HU) 21.63 ± 1.47/22.49 ± 2.11 17.61 ± 0.95/17.77 ± 2.14 23.64 ± 1.09/25.03 ± 2.12 22.63 ± 2.68/22.81 ± 3.31 Change (%) 4.72 ± 19.55 1.39 ± 21.32 6.14 ± 18.19 2.41 ± 25.64 Entropy, filter scale value N Bsl/AT 5.26 ± 0.17/5.13 ± 0.31 5.96 ± 0.54/5.97 ± 0.99 6.16 ± 0.47/5.97 ± 0.61 5.85 ± 0.29/5.85 ± 0.45 Change (%) −2.47 ± 7.54 0.15 ± 4.35 −3.14 ± 5.47 −0.41 ± 6.61 1.0 Bsl/AT 5.14 ± 0.54/4.88 ± 0.59 5.24 ± 0.58/5.04 ± 0.34 6.37 ± 0.49/6.15 ± 0.42 5.52 ± 0.45/5.32 ± 0.51 Change (%) −5.16 ± 13.16 −3.42 ± 11.49 −3.52 ± 11.93 −3.43 ± 12.75 1.5 Bsl/AT 4.45 ± 0.42/4.15 ± 0.56 3.98 ± 0.61/3.51 ± 0.52 5.47 ± 0.48/5.08 ± 0.59 3.72 ± 0.63/3.45 ± 0.62 Change (%) −8.78 ± 19.91 −11.27 ± 22.15 −6.01 ± 19.14 −6.86 ± 21.26 2.0 Bsl/AT 3.33 ± 0.69/2.81 ± 0.51 3.26 ± 0.48/2.84 ± 0.59 3.88 ± 0.45/3.53 ± 0.53 3.28 ± 0.77/2.99 ± 0.83 Change (%) −12.72 ± 29.46 −13.81 ± 31.08 −8.29 ± 28.47 −7.99 ± 29.62 2.5 Bsl/AT 2.39 ± 0.61/2.29 ± 0.70 2.58 ± 0.54/2.36 ± 0.41 3.14 ± 0.55/2.96 ± 0.63 2.67 ± 0.74/2.47 ± 0.86 Change (%) −4.02 ± 33.41 −8.72 ± 30.93 −7.27 ± 27.64 −8.12 ± 30.09 Uniformity, filter scale value N Bsl/AT 0.006 ± 0.001/0.007 ± 0.002 0.008 ± 0.001/0.010 ± 0.001 0.003 ± 0.001/0.004 ± 0.001 0.007 ± 0.001/0.008 ± 0.002 Change (%) 19.06 ± 26.47 17.68 ± 25.29 17.49 ± 28.25 15.41 ± 25.78 1.0 Bsl/AT 0.007 ± 0.002/0.008 ± 0.002 0.006 ± 0.001/0.007 ± 0.001 0.002 ± 0.000/0.004 ± 0.001 0.005 ± 0.001/0.006 ± 0.001 Change (%) 11.07 ± 22.94 13.75 ± 23.23 16.14 ± 18.26 17.41 ± 19.64 1.5 Bsl/AT 0.014 ± 0.003/0.016 ± 0.002 0.016 ± 0.002/0.018 ± 0.003 0.009 ± 0.001/0.011 ± 0.002 0.016 ± 0.001/0.017 ± 0.003 Change (%) 9.37 ± 21.09 9.74 ± 20.21 8.99 ± 17.62 9.16 ± 15.64 2.0 Bsl/AT 0.035 ± 0.014/0.037 ± 0.013 0.045 ± 0.009/0.049 ± 0.011 0.032 ± 0.005/0.033 ± 0.005 0.058 ± 0.007/0.061 ± 0.011 Change (%) 6.24 ± 19.11 9.85 ± 16.82 4.75 ± 11.74 5.37 ± 11.56 2.5 Bsl/AT 0.088 ± 0.007/0.090 ± 0.016 0.103 ± 0.008/0.114 ± 0.013 0.063 ± 0.007/0.064 ± 0.009 0.069 ± 0.021/0.077 ± 0.018 Change (%) 1.41 ± 17.26 8.72 ± 12.99 2.36 ± 11.33 5.95 ± 9.46</p><p>AT, after two treatment cycle; AV, attenuation value; Bsl, baseline; HU, Hounsfield units; N, without filtration.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Discriminantscore=1.6×x+1.4×y−0.8×z+0.199 Discriminant</p><p>score</p><p>=</p><p>1.6</p><p>×</p><p>x</p><p>+</p><p>1.4</p><p>×</p><p>y</p><p>−</p><p>0.8</p><p>×</p><p>z</p><p>+</p><p>0.199</p><p>where <em>x</em> is the change of size, <em>y</em> is the change of attenuation value, and <em>z</em> is the change of uniformity with a filter scale value of 2.5. When the discriminant score is ≧0, it predicts that the patient will have a good response to therapy, whereas scores &lt;0 predict a poor response.</p><p>Table 3</p><p>Evaluation of Response to Therapy</p><p>Method Exploration Sample Validation Sample ROC Threshold_P_ Value_P_ Value RECIST Not applicable .17 .21 AV Bsl/AT (HU) ≦18.14/≦19.27 .32/.29 .87/.83 Change (%) ≦2.12 .42 .49 Entropy, filter scale value N Bsl/AT ≧5.32/≧5.24 .27/.25 .43/.64 Change (%) ≧−1.16 .48 .47 1.0 Bsl/AT ≧5.19/≧4.93 .33/.39 .67/.63 Change (%) ≧−3.99 .52 .89 1.5 Bsl/AT ≦4.11/≦3.89 .65/.49 .87/.85 Change (%) ≦−9.77 .42 .72 2.0 Bsl/AT ≦3.29/≧2.83 .72/.88 .80/.93 Change (%) ≧−1.16 .74 .73 2.5 Bsl/AT ≧2.43/≧2.31 .27/.61 .57/.74 Change (%) ≦−5.63 .35 .58 Uniformity, filter scale value N Bsl/AT ≧0.007/≧0.009 .82/.59 .72/.92 Change (%) ≦18.11 .27 .53 1.0 Bsl/AT ≦0.007/≦0.008 .68/.74 .90/.97 Change (%) ≧13.12 .23 .72 1.5 Bsl/AT ≧0.016/≧0.017 .45/.42 .89/.85 Change (%) ≧9.62 .38 .51 2.0 Bsl/AT ≧0.041/≧0.043 .11/.07 .61/.79 Change (%) ≧6.98 .19 .39 2.5 Bsl/AT ≧0.095/≧0.102 .21/.176 .74/.81 Change (%) ≧4.73 .13 .16 Discriminant score Not applicable .02 .04</p><p>AT, after two treatment cycle; AV, attenuation value; Bsl, baseline; HU, Hounsfield units; RECIST, Response Evaluation Criteria in Solid Tumors; N, without filtration.</p><p><em>P</em> values were obtained with Kaplan–Meier analysis.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EvaluationofClinicalOutcomesofAntiangiogenicTargetedTherapyinPatientswithPulmonaryMetastaticRenalCellCarcinomaUsingNonContrastEnhancedComputedTomography/1_1s20S1076633214002359.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/EvaluationofClinicalOutcomesofAntiangiogenicTargetedTherapyinPatientswithPulmonaryMetastaticRenalCellCarcinomaUsingNonContrastEnhancedComputedTomography/1_1s20S1076633214002359.jpg" alt="Figure 2, Kaplan–Meier curves show the proportion of patients without disease progression, as determined by Response Evaluation Criteria in Solid Tumors, and the percentage change for the attenuation value, uniformity (filter scale value: 2.5), and discrimination analysis in the validation sample group. PD, progressive disease; PR, partial response; SD, stable disease." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Jemal A., Murray T., Samuels A., et. al.: Cancer statistics. CA Cancer J Clin 2003; 53: pp. 5-26.</p><li><p>2. Escudier B., Eisen T., Stadler W.M., et. al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: pp. 125-134.</p><li><p>3. Motzer R.J., Hutson T.E., Tomczak P., et. al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: pp. 115-124.</p><li><p>4. Rini B.I., Wilding G., Hudes G., et. al.: Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: pp. 4462-4468.</p><li><p>5. Rixe O., Bukowski R.M., Michaelson M.D., et. al.: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8: pp. 975-984.</p><li><p>6. Eisenhauer E.A., Therasse P., Bogaerts J., et. al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: pp. 228-247.</p><li><p>7. Ruan M., Shen Y., Chen L., et. al.: RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma. Oncol Lett 2013; 6: pp. 480-486.</p><li><p>8. Smith A.D., Lieber M.L., Shah S.N.: Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010; 194: pp. 157-165.</p><li><p>9. Smith A.D., Shah S.N., Rini B.I., et. al.: Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194: pp. 1470-1478.</p><li><p>10. Therasse P., Arbuck S.G., Eisenhauer E.A., et. al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: pp. 205-216.</p><li><p>11. Ganeshan B., Miles K.A., Young R.C., et. al.: In search of biologic correlates for liver texture on portal phase CT. Acad Radiol 2007; 14: pp. 1058-1068.</p><li><p>12. Ganeshan B., Miles K.A., Young R.C., et. al.: Hepatic entropy and uniformity: additional parameters that can potentially increase the effectiveness of contrast enhancement during abdominal CT. Clin Radiol 2007; 62: pp. 761-768.</p><li><p>13. Fossa S.D.: Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27: pp. 187-193.</p><li><p>14. Karumanchi S.A., Merchan J., Sukhatme V.P.: Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002; 11: pp. 37-42.</p><li><p>15. Hiles J.J., Kolesar J.M.: Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008; 65: pp. 123-131.</p><li><p>16. van der Veldt A.A, Meijerink M.R., van den Eertwegh A.J., et. al.: Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 2010; 5: pp. 95-112.</p><li><p>17. Uhrig M., Sedlmair M., Schlemmer H.P., et. al.: Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. Cancer Imaging 2013; 13: pp. 306-313.</p><li><p>18. Baccala A., Hedgepeth R., Kaouk J., et. al.: Pathologic evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14: pp. 1095-1097.</p><li><p>19. Flaherty K.T.: Sorafenib in renal cell carcinoma. Clin Cancer Res 2007; 13: pp. 747-752.</p><li><p>20. Van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et. al.: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010; 102: pp. 803-809.</p><li><p>21. Nathan P.D., Vinayan A., Stott D., et. al.: CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010; 9: pp. 15-19.</p><li><p>22. Goh V., Ganeshan B., Nathan P., et. al.: Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011; 261: pp. 165-171.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-21/'>Volume 21</a>, <a href='/categories/issue-11/'>Issue 11</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Evaluation%20of%20Clinical%20Outcomes%20of%20Antiangiogenic-Targeted%20Therapy%20in%20Patients%20with%20Pulmonary%20Metastatic%20Renal%20Cell%20Carcinoma%20Us%20ing%20Non%E2%80%93Contrast-Enhanced%20Computed%20Tomography%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fevaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Evaluation%20of%20Clinical%20Outcomes%20of%20Antiangiogenic-Targeted%20Therapy%20in%20Patients%20with%20Pulmonary%20Metastatic%20Renal%20Cell%20Carcinoma%20Us%20ing%20Non%E2%80%93Contrast-Enhanced%20Computed%20Tomography%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fevaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fevaluation-of-clinical-outcomes-of-antiangiogenic-targeted-therapy-in-patients-with-pulmonary-metast%2F&text=Evaluation%20of%20Clinical%20Outcomes%20of%20Antiangiogenic-Targeted%20Therapy%20in%20Patients%20with%20Pulmonary%20Metastatic%20Renal%20Cell%20Carcinoma%20Us%20ing%20Non%E2%80%93Contrast-Enhanced%20Computed%20Tomography%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/a-retrospective-study-of-chest-tomosynthesis-as-a-tool-for-optimizing-the-use-of-computed-tomography/"><div class="card-body"> <em class="small" data-ts="1414774800" data-df="ll" > Oct 31, 2014 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Retrospective Study of Chest Tomosynthesis as a Tool for Optimizing the use of Computed Tomography Resources and Reducing Patient Radiation Exposure</h3><div class="text-muted small"><p> Rationale and Objectives To investigate potential benefits and drawbacks of the clinical use of chest tomosynthesis (CTS), to what extent CTS obviates the need for chest computed tomography (CT), ...</p></div></div></a></div><div class="card"> <a href="/posts/automated-assessment-of-renal-cortical-surface-roughness-from-computerized-tomography-images-and-its/"><div class="card-body"> <em class="small" data-ts="1414774800" data-df="ll" > Oct 31, 2014 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Assessment of Renal Cortical Surface Roughness From Computerized Tomography Images and Its Association with Age</h3><div class="text-muted small"><p> Rationale and Objectives Nephrosclerosis occurs with aging and is characterized by increased kidney subcapsular surface irregularities at autopsy. Assessments of cortical roughness in vivo could p...</p></div></div></a></div><div class="card"> <a href="/posts/breast-mri-bi-rads-assessments-and-abnormal-interpretation-rates-by-clinical-indication-in-us-commun/"><div class="card-body"> <em class="small" data-ts="1414774800" data-df="ll" > Oct 31, 2014 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Breast MRI BI-RADS Assessments and Abnormal Interpretation Rates by Clinical Indication in US Community Practices</h3><div class="text-muted small"><p> Rationale and Objectives As breast magnetic resonance imaging (MRI) use grows, benchmark performance parameters are needed for auditing and quality assurance purposes. We describe the variation in...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/contrast-enhanced-spectral-mammography/" class="btn btn-outline-primary" prompt="Older"><p>Contrast-Enhanced Spectral Mammography</p></a> <a href="/posts/how-mammographic-breast-density-affects-radiologists-visual-search-patterns/" class="btn btn-outline-primary" prompt="Newer"><p>How Mammographic Breast Density Affects Radiologists' Visual Search Patterns</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
